General Information of Drug (ID: DMFMKQ3)

Drug Name
LY3015014 Drug Info
Indication
Disease Entry ICD 11 Status REF
Cardiovascular disease BA00-BE2Z Phase 2 [1]
Cross-matching ID
TTD Drug ID
DMFMKQ3

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
REGN-727 DM87XSN Familial hypercholesterolemia 5C80.00 Approved [3]
Evolocumab DMNSAND Heterozygous familial hypercholesterolemia 5C80.00 Approved [4]
Bococizumab DM2OBNW Chronic obstructive pulmonary disease CA22 Phase 3 [2]
PF-04950615 DM0TWCY Hypercholesterolaemia 5C80.0 Phase 3 [5]
AMG 145 DMG324Y Hypercholesterolaemia 5C80.0 Phase 3 [6]
LIB003 DMVP8WU Hypercholesterolaemia 5C80.0 Phase 3 [7]
MK-0616 DMVGMNC Hypercholesterolaemia 5C80.0 Phase 2 [8]
PCSK9 Adnectin DMH86KO Cardiovascular disease BA00-BE2Z Phase 1 [9]
SPC5001 DMUPQ70 Hyperlipidaemia 5C80 Phase 1 [10]
AZD0780 DMAFPNI Elevated Lipoprotein(a) 5C80.1 Phase 1 [11]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Proprotein convertase subtilisin/kexin type 9 (PCSK9) TTBRG7E PCSK9_HUMAN Not Available [2]

References

1 ClinicalTrials.gov (NCT01890967) A Study of LY3015014 in Participants With High Cholesterol. U.S. National Institutes of Health.
2 The dyslipidaemia market. Nat Rev Drug Discov. 2014 Nov;13(11):807-8.
3 Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial. Lancet. 2012 Jul 7;380(9836):29-36.
4 Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med. 2017 May 4;376(18):1713-1722.
5 Phase 3 data for PCSK9 inhibitor wows. Nat Biotechnol. 2013 Dec;31(12):1057-8.
6 PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. Lancet. 2015 Jan 24;385(9965):331-40.
7 ClinicalTrials.gov (NCT05234775) Cross-Over Study to Compare the Pharmacokinetics and Pharmacodynamics of LIB003 Process 1 and Process 2 Drug Product in Subjects With or Without Statin Therapy. U.S.National Institutes of Health.
8 Phase 2b Randomized Trial of the Oral PCSK9 Inhibitor MK-0616. J Am Coll Cardiol. 2023 Apr 25;81(16):1553-1564.
9 Pharmacologic profile of the Adnectin BMS-962476, a small protein biologic alternative to PCSK9 antibodies for low-density lipoprotein lowering. J Pharmacol Exp Ther. 2014 Aug;350(2):412-24.
10 2011 Pipeline of Santaris Pharma.
11 Clinical pipeline report, company report or official report of AstraZeneca